# Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT03522584** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Durvalumab
- **OTHER:** Laboratory Biomarker Analysis
- **RADIATION:** Stereotactic Body Radiation Therapy
- **BIOLOGICAL:** Tremelimumab
- **PROCEDURE:** Hypofractionated Image-Guided Radiation Therapy

## Key facts

- **NCT ID:** NCT03522584
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-17
- **Primary completion:** 2021-12-16
- **Final completion:** 2022-01-19
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Terminated by the sponsor due to lack of efficacy in study treatment.
- **Last updated:** 2023-06-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03522584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03522584, "Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03522584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*